Bright Minds Biosciences (DRUG) Price & Analysis

Compare

68 Followers

DRUG Stock Chart & Stats

C$111.87

C$0.00(0.00%)

At close: Jan 07 4:00 PM EST

C$111.87

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$33.01 - C$170.00

Previous CloseN/A

Volume70.00

Average Volume (3M)451.00

Market Cap

C$1.07B

Enterprise ValueC$788.35M

Total Cash (Recent Filing)C$82.91M

Total Debt (Recent Filing)C$125.78K

Price to Earnings (P/E)―

Beta28.62

Next Earnings

Feb 18, 2026

EPS Estimate

-1.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding9,732,161

10 Day Avg. Volume620

30 Day Avg. Volume451

Financial Highlights & Ratios

PEG Ratio-0.27

Price to Book (P/B)7.07

Price to Sales (P/S)0.00

P/FCF Ratio-66.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$163.74

Price Target Upside46.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 results demonstrated substantial reductions in absence seizures and total seizure time on 24-hour EEG in a highly treatment-resistant population, supporting strong clinical efficacy.

Differentiated Pharmacology And Safety ProfileUnique pharmacology, favorable pharmacokinetics and a clean Phase 1 safety profile, coupled with objective EEG endpoints, support best-in-class potential and help de-risk further development.

Pipeline Expansion Into Prader-Willi SyndromeInitiation of a Phase 2a study of BMB-101 and advancement of BMB-105 extend the 5-HT2C program into Prader-Willi Syndrome, potentially opening a high-need market beyond seizure disorders.

Bears Say

Competitive LandscapeThe drug trails an established competitor within the same development class, which could constrain market share and pricing power if commercialization proceeds.

Financing And Dilution RiskPlanned future equity raises pose a dilution risk for existing shareholders and could exert downward pressure on valuation.

Long-term Safety UncertaintyLong-term safety remains uncertain and additional safety data are required to fully assess tolerability in broader patient populations.

Bright Minds Biosciences News

Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

22d ago

CMPS

DRUG

Bright Minds 1.945M share Secondary priced at $90.00

The deal size was increased to $175M in common stock from $100M in common stock. Jefferies, TD Cowen,...

22d ago

DRUG

Bright Minds price target raised to $142 from $82 at Baird

Baird raised the firm’s price target on Bright Minds (DRUG) to $142 from $82 and keeps an Outperform...

23d ago

DRUG

Bright Minds price target raised to $147 from $72 at BTIG

BTIG raised the firm’s price target on Bright Minds (DRUG) to $147 from $72 and keeps a Buy...

23d ago

DRUG

Bright Minds announces $100M common shares offering

Bright Minds (DRUG) Biosciences announced the launch of a public offering of common shares in the capital of...

24d ago

DRUG

Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101

Bright Minds (DRUG) Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating...

24d ago

DRUG

Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline

The latest update is out from Bright Minds Biosciences ( ($TSE:DRUG) ). On January 9, 2026, Bright Minds...

21d ago

DRUG

Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline

An announcement from Bright Minds Biosciences ( ($TSE:DRUG) ) is now available. On January 7, 2026, Bright Minds...

21d ago

DRUG

Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program

An update from Bright Minds Biosciences ( ($TSE:DRUG) ) is now available. On January 7, 2026, Bright Minds...

22d ago

DRUG

Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor

Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an update. On January 7, 2026, Bright Minds Biosciences Inc....

23d ago

DRUG

Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline

Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an update. On January 6, 2026, Bright Minds Biosciences Inc....

23d ago

DRUG

Bright Minds Biosciences: Encouraging BMB-101 Efficacy, Pipeline Expansion, and Valuation Upside Support Maintained Buy Rating

Analyst Thomas Shrader from BTIG maintained a Buy rating on Bright Minds Biosciences and increased the price target...

23d ago

DRUG

Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders

Bright Minds Biosciences ( ($TSE:DRUG) ) has shared an update. On January 6, 2026, Bright Minds Biosciences reported...

24d ago

DRUG

Bright Minds Biosciences: Robust BMB-101 Phase 2 Data and Clear Registrational Path Underpin $115 Target and Buy Rating

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences and keeping the price...

24d ago

DRUG

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was C$33.01 and its highest was C$170.00 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$1.07B.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Feb 18, 2026 which is in 19 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on Dec 24, 2025. The company reported -C$0.61 earnings per share for the quarter, beating the consensus estimate of -C$0.784 by C$0.174.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -1.29.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 9,732,161 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -C$0.61 in its last earnings report, beating expectations of -C$0.784. Following the earnings report the stock price went up 2.111%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in TSE:DRUG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bright Minds Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.79%

Trailing 12-Months

Asset Growth

736.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Bright Minds Biosciences (DRUG) Earnings & Revenues

Historic Earnings Reports

DRUG Stock 12 Month Forecast

Average Price Target

C$163.74

▲(46.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"C$35","76":"C$76","117":"C$117","158":"C$158","199":"C$199"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198.92553177000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$198.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":163.74142411,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$163.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.25879280000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$108.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,76,117,158,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.43,117.23734859769232,124.04469719538463,130.85204579307694,137.65939439076925,144.46674298846156,151.27409158615387,158.08144018384615,164.8887887815385,171.69613737923078,178.50348597692312,185.3108345746154,192.1181831723077,{"y":198.92553177000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.43,114.53087877769231,118.63175755538462,122.73263633307693,126.83351511076924,130.93439388846156,135.03527266615384,139.13615144384616,143.23703022153848,147.33790899923076,151.43878777692308,155.5396665546154,159.64054533230768,{"y":163.74142411,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.43,110.26298406153848,110.09596812307693,109.9289521846154,109.76193624615385,109.59492030769232,109.42790436923077,109.26088843076924,109.0938724923077,108.92685655384616,108.75984061538462,108.59282467692309,108.42580873846154,{"y":108.25879280000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >